Related Experiment Video
Updated: Jul 19, 2025

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods
Published on: December 21, 2019
TRIM5α restricts poxviruses and is antagonized by CypA and the viral protein C6
Yiqi Zhao1,2, Yongxu Lu1,2, Samuel Richardson3
1Department of Pathology, University of Cambridge, Cambridge, UK.
Abstract:
Human tripartite motif protein 5α (TRIM5α) is a well-characterized restriction factor for some RNA viruses, including HIV1-5; however, reports are limited for DNA viruses6,7. Here we demonstrate that TRIM5α also restricts orthopoxviruses and, via its SPRY domain, binds to the orthopoxvirus capsid protein L3 to diminish virus replication and activate innate immunity. In response, several orthopoxviruses, including vaccinia, rabbitpox, cowpox, monkeypox, camelpox and variola viruses, deploy countermeasures. First, the protein C6 binds to TRIM5 via the RING domain to induce its proteasome-dependent degradation. Second, cyclophilin A (CypA) is recruited via interaction with the capsid protein L3 to virus factories and virions to antagonize TRIM5α; this interaction is prevented by cyclosporine A (CsA) and the non-immunosuppressive derivatives alisporivir and NIM811. Both the proviral effect of CypA and the antiviral effect of CsA are dependent on TRIM5α. CsA, alisporivir and NIM811 have antiviral activity against orthopoxviruses, and because these drugs target a cellular protein, CypA, the emergence of viral drug resistance is difficult. These results warrant testing of CsA derivatives against orthopoxviruses, including monkeypox and variola.
Insights
Human TRIM5α (tripartite motif protein 5α) restricts orthopoxviruses by binding their capsid protein L3. Viral proteins C6 and cyclophilin A counteract this, but drugs like CsA inhibit them, offering antiviral potential.
Area of Science:
- Virology
- Immunology
- Cell Biology
Background:
- Human tripartite motif protein 5α (TRIM5α) is known to restrict certain RNA viruses like HIV.
- Its role in restricting DNA viruses, particularly orthopoxviruses, is less understood.
Purpose of the Study:
- To investigate the antiviral activity of TRIM5α against orthopoxviruses.
- To identify viral countermeasures and potential therapeutic targets.
Main Methods:
- Demonstrated TRIM5α restriction of orthopoxviruses through SPRY domain binding to the L3 capsid protein.
- Identified viral protein C6 and cyclophilin A (CypA) as counteracting factors.
- Assessed the antiviral effects of cyclosporine A (CsA) and its derivatives (alisporivir, NIM811) in vitro.
Main Results:
- TRIM5α restricts orthopoxviruses by binding the L3 capsid protein, inhibiting replication and activating innate immunity.
- Orthopoxviruses employ C6 to degrade TRIM5α and CypA to antagonize TRIM5α via L3 interaction.
- CsA, alisporivir, and NIM811 inhibit CypA, demonstrating antiviral activity against orthopoxviruses dependent on TRIM5α.
Conclusions:
- TRIM5α acts as a restriction factor against orthopoxviruses.
- Viral countermeasures involve TRIM5α degradation and antagonism by CypA.
- CsA derivatives show promise as antiviral therapies against orthopoxviruses due to targeting the host factor CypA, limiting resistance emergence.
Related Concept Videos
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Inhibition of Cdk Activity
Mechanisms of Retrovirus-induced Cancers
Retroviruses

